Subcutaneous trastuzumab (herceptin) vs intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit
European Journal of Obstetrics & Gynecology and Reproductive Biology | Dec 12, 2017
Survival in patients with primary Dermatofibrosarcoma Protuberans: National Cancer Data Base analysis
Journal of the American Academy of Dermatology | Dec 09, 2017